Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

Q2 2025 Earnings Call Transcript August 5, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with ...

Few patients with MDS receive treatment with hypomethylating agents, with evidence of age-, sex-, and race-related disparities.

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical ...